Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy

Prenatal Diagnosis

Volumn 29, Issue 9, 2009, Pages 847-851

  Akolekar, Ranjit ^a   Casagrandi, Davide ^a   Skyfta, Evdoxia ^a   Ahmed, Abubaker Abdalla ^a   Nicolaides, Kypros H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Angiopoietin 2; First trimester screening; Preeclampsia; Uterine artery Doppler

Indexed keywords

ANGIOPOIETIN 2; GROWTH FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MATERNAL SERUM; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPRODUCTION; UTERINE ARTERY;

ADULT; ANGIOPOIETIN-2; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MOTHERS; PARITY; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; ULTRASONOGRAPHY, DOPPLER; ULTRASONOGRAPHY, PRENATAL;

EID: 69749092722     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2307     Document Type: Article

References (24)

1. Akolekar R, Zaragoza E, Poon LCY, Pepes S, Nicolaides KH. 2008. Maternal serum placental growth factor (PlGF) at 11 + 0 to 13 + 6 weeks of gestation in hypertensive disorders of pregnancy. Ultrasound Obstet Gynecol 32: 732-739.
2. Carmeliet P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395.
3. Charnock-Jones DS, Kaufmann P, Mayhew TM. 2004. Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta 25: 103-113. (Pubitemid 38248055)
4. Davey DA, MacGillivray I. 1988. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 158: 892-898. (Pubitemid 18106884)
5. Ferrara N. 2000. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55: 15-35. (Pubitemid 32094444)
6. Geva E, Ginzinger DG, Zaloudek CJ, et al. 2002. Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab 87: 4213-4224.
7. Hirokoshi K, Maeshima Y, Kobayashi K, et al. 2005. Increase of serum angiopoietin-2 during pregnancy is suppressed in women with preeclampsia. Am J Hypertens 18: 1181-1188. (Pubitemid 41337970)
8. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. 2008. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin, and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 31: 618-624.
9. Khong TY, De Wolf F, Robertson WB, Brosens I. 1986. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 93: 1049-1059. (Pubitemid 16004866)
10. Levine RJ, Maynard SE, Qian C, et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683. (Pubitemid 38364626)
11. Maisonpierre PC, Suri C, Jones PF, et al. 1997. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60. (Pubitemid 27450643)
12. Maynard S, Epstein FH, Karumanchi SA. 2008. Preeclampsia and angiogenic imbalance. Annu Rev Med 59: 61-78.
13. Nadar SK, Karalis I, Al Yemeni E, Blann AD, Lip GY. 2005. Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb Haemost 94: 1071-1076. (Pubitemid 41645951)
14. Pijnenborg R, Anthony J, Davey DA, et al. 1991. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 98: 648-655.
15. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. 2007. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 30: 742-749. (Pubitemid 47612696)
16. Poon LCY, Maiz N, Valencia C, Plasencia W, Nicolaides KH. 2009. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 33: 23-33.
17. Seval Y, Sati L, Celik-Ozenci C, Taskin O, Demir R. 2008. The distribution of angiopoietin-1, angiopoietin-2 and their receptors tie-1 and tie-2 in the very early human placenta. Placenta 29: 809-815.
18. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352: 343-346.
19. Steinberg G, Khankin EV, Karumanchi SA. 2009. Angiogenic factors and preeclamsia. Thromb Res 123: S93-S99.
20. Suri C, Jones PF, Patan S, et al. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180. (Pubitemid 27010101)
21. Wang Y, Tasevski V, Wallace EM, Gallery ED, Morris JM. 2007. Reduced maternal serum concentrations of angiopoietin-2 in the first trimester precede intrauterine growth restriction associated with placental insufficiency. BJOG 114: 1427-1431. (Pubitemid 47609950)
22. Yancopoulos GD, Davis S, Gale NW, et al. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248.
23. Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH. 2005. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 193: 429-436.
24. Zhang EG, Smith SK, Baker PN, Charnock-Jones DS. 2001. The regulation and localisation of angiopoietin-1, -2 and their receptor Tie2 in normal and pathologic human placentae. Mol Med 7: 624-635.